A legal prescription should settle one question: whether a patient is using an authorised medicine under clinical care. Too often, patients say it instead opens another argument — with a GP, an employer or another part of the healthcare system — about whether their treatment is legitimate at all.
That is the stigma gap left behind by the 2018 law change.
Law moved faster than understanding
Cannabis-based medicines entered specialist prescribing without becoming familiar across the wider health service. Many professionals received little training on products, documentation or the practical implications of treatment. Patients can therefore meet very different levels of knowledge depending on who happens to see them.
Scepticism is not always prejudice; clinicians are entitled to ask about evidence, interactions and risk. The problem begins when a patient is dismissed because the medicine is cannabis rather than assessed on the same clinical principles applied to other prescriptions.
Consequences beyond awkward conversations
Misunderstanding can affect shared care, emergency treatment and referrals. Reports from patients about transplant pathways and other specialist services are especially serious because decisions may carry life-changing consequences.
Those cases require careful examination. A clinical team may have legitimate concerns about intoxication, smoking, adherence or interactions, but it should distinguish those issues from lawful, monitored use of a prescribed product. A blanket assumption is not a substitute for an individual risk assessment.
Education is patient safety
Better professional training is sometimes framed as advocacy. It is more accurately a safety measure. Clinicians need to know what these medicines are, how prescriptions are evidenced and when specialist advice is necessary. Patients need confidence that disclosing treatment will improve their care rather than expose them to judgement.
Normalisation does not mean removing scrutiny. It means applying scrutiny consistently. Until cannabis-based medicines are treated as medicines first — with benefits, risks and individual circumstances — legal reform will continue to feel incomplete to the people it was meant to help.
